

Atıflar

* **Tüzel, E.**, K. Yörükoğlu, B. Gümüş ve Z. Kırkalı, "Testicular microlithiasis associated with teratocarcinoma and intratubular germ cell neoplasia: A case report", *Int J Urol*, **4(5)**, 530-532 (1997)

1. Kim B, Winter TC, Ryu JA, "Testicular microlithiasis: clinical significance and review of the literature", *EUROPEAN RADIOLOGY* 13(12):2567-2576 (2003)
2. Miller FNAC, Sidhu PS, "Does testicular microlithiasis matter? A review", *CLINICAL RADIOLOGY* 57(10):883-890 (2002)
3. Dell'Acqua A, Toma P, Oddone M, Ciccone MA, Marsili E, Derchi LE, "Testicular microlithiasis: US findings in six pediatric cases and literature review", *EUROPEAN RADIOLOGY* 9(5):940-944 (1999)

* **Tüzel, E.**, M. Sevinç, F. Obuz, M. Sade ve Z. Kırkalı, "Is magnetic resonance imaging necessary in the staging of prostate cancer ?", *Urol Int*, 61(4), 227-231 (1999).

4. Bucerius J, Ahmadzadehfar H, Hortling N, et al. , "Incidental diagnosis of a PSA-negative prostate cancer by (18)FDG PET/CT in a patient with hypopharyngeal cancer", *PROSTATE CANCER AND PROSTATIC DISEASES*, 10(3): 307-310 (2007)
5. Aigner F, Pallwein L, Pelzer A, et al. , " Value of magnetic resonance imaging in prostate cancer diagnosis", *WORLD JOURNAL OF UROLOGY*, 25(4):351-359 (2007)
6. Akin O, Hricak H, "Imaging of prostate cancer", *RADIOLOGIC CLINICS OF NORTH AMERICA* 45 (1): 207 (2007).
7. Mulkern RV, Barnes AS, Haker SJ et al., "Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range", *MAGNETIC RESONANCE IMAGING* 24 (5): 563-568 (2006).
8. Wang L, Hricak H, Kattan MW, et al, "Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer", *AMERICAN JOURNAL OF ROENTGENOLOGY* 186 (3): 743-748 (2006).
9. Sung J, Espiritu JI, Segall GM, et al, "Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer", *BJU INTERNATIONAL* 92 (1): 24-27 (2003).
10. Purohit RS, Shinohara K, Meng MV, et al. , "Imaging clinically localized prostate cancer", *UROLOGIC CLINICS OF NORTH AMERICA* 30 (2): 279 (2003)
11. Eng TY, Thomas CR, Herman TS, "Primary radiation therapy for localized prostate cancer", *UROLOGIC ONCOLOGY* 7 (6): 239-257 (2002).
12. Kuhn M, Huttmann P, Spielhauer E, et al., "Clinical value of native and contrast-enhanced MRI for staging prostatic carcinoma prior to radical prostatectomy", *ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN* 173 (7): 595-600 (2001).

13. Medica M, Giglio M, Germinale F, et al., "Roach's mathematical equations in predicting pathological stage in men with clinically localized prostate cancer", *TUMORI* 87 (3): 130-133 (2001)

* Kirkalı, G., **E. Tüzel**, C. Güler, S. Gezer ve Z. Kirkalı, "Significance of tissue laminin P₁, elastase and fibronectin levels in transitional cell carcinoma of the bladder", *Eur Urol*, **39(3)**, 292-299 (**2001**).

14. Tokyol C, Koken T, Demirbas M, et al. , "Expression of cathepsin D in bladder carcinoma: Correlation with pathological features and serum cystatin C levels", *TUMORI* 92 (3): 230-235 (2006).

15. Elsamman E, Fukumori T, Ewis AA, et al. , "Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: Preliminary results", *UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS* 24 (2): 109-115 (2006).

16. Ioachim E, Michael M, Stavropoulos NE, et al., "A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma", *BJU INTERNATIONAL* 95 (4): 655-659 (2005).

17. Gontero P, Banisadr S, Frea B, et al. , "Metastasis markers in bladder cancer: A review of the literature and clinical considerations", *EUROPEAN UROLOGY* 46(3): 296-311 (2004).

18. Kirkali Z, Lekili M, "Renal cell carcinoma: new prognostic factors?", *CURRENT OPINION IN UROLOGY* 13 (6): 433-438 (2003).

19. Hegele A, Heidenreich A, Varga Z, et al., "Cellular fibronectin in patients with transitional cell carcinoma of the bladder", *UROLOGICAL RESEARCH* 30 (6): 363-366 (2003).

20. Eissa S, Swellam M, Sadek M, et al., "Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors, " *JOURNAL OF UROLOGY* 168 (2): 465-469 (2002).

21. Siemianowicz K, Gminski J, Francuz T, et al. , "Fibronectin gene polymorphism in patients with lung cancer, " *ONCOLOGY REPORTS* 8 (6): 1289-1292 (2001).

* **Tüzel, E.**, Z. Kirkalı, K. Yörükoğlu, M.U. Mungan ve M. Sade, "Metallothionein expression in renal cell carcinoma: Subcellular localization and prognostic significance", *J Urol*, 165(5), 1710-1713 (**2001**).

22. Pedersen MO, Larsen A, Stoltenberg M, et al., "The role of metallothionein in oncogenesis and cancer prognosis", *PROGRESS IN HISTOCHEMISTRY AND CYTOCHEMISTRY*, 44(1):29-64 (2009)

23. Szajerka A, Dziegiel P, Szajerka T, et al., "Immunohistochemical Evaluation of Metallothionein, Mcm-2 and Ki-67 Antigen Expression in Tumors of the Adrenal Cortex", *ANTICANCER RESEARCH* 28(5B): 2959-2965 (2008).

- 24.** Hinkel A, Schmidtchen S, Palisaar RJ, et al., "Identification of bladder cancer patients at risk for recurrence or progression: An immunohistochemical study based on the expression of metallothionein", *JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A*, 71(13-14): 954-959 (2008).
- 25.** Pastuszewski W, Dziegiel P, Krecicki T, et al. , "Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer", *ANTICANCER RESEARCH* 27(1A): 335-342 (2007).
- 26.** Yamasaki Y, Smith C, Weisz D, et al, "Metallothionein expression as prognostic factor for transitional cell carcinoma of bladder, " *UROLOGY* 67 (3): 530-535 (2006).
- 27.** Han WK, Alinani A, Wu CL, et al. , "Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma, " *JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY* 16 (4): 1126-1134 (2005).
- 28.** Theocharis SE, Margeli AP, Klijanienko JT, et al., "Metallothionein expression in human neoplasia, " *HISTOPATHOLOGY* 45 (2): 103-118 (2004).
- 29.** Kirkali Z, Lekili M., "Renal cell carcinoma: new prognostic factors?, " *CURRENT OPINION IN UROLOGY* 13 (6): 433-438 (2003).
- 30.** Shimoda R, Achanzar WE, Qu W, et al., "Metallothionein is a potential negative regulator of apoptosis, " *TOXICOLOGICAL SCIENCES* 73 (2): 294-300 (2003).
- 31.** Benchekroun A, Nouini Y, Zannoud M, et al., "Sarcomatoid carcinoma of the kidney: a case report, " *ANNALES D UROLOGIE* 37 (1): 5-7 (2003).
- 32.** Huang GW, Yang LY, "Metallothionein expression in hepatocellular carcinoma, " *WORLD JOURNAL OF GASTROENTEROLOGY* 8 (4): 650-653 (2002).
- 33.** Janssen AML, van Duijn W, Kubben FJGM et al. , "Prognostic significance of metallothionein in human gastrointestinal cancer, " *CLINICAL CANCER RESEARCH* 8 (6): 1889-1896 (2002)
- 34.** Godley P, Kim SW, " Renal cell carcinoma, " *CURRENT OPINION IN ONCOLOGY* 14 (3): 280-285 (2002).

* Kirkali, Z., **E. Tüzel** ve M.U. Mungan, "Recent advances in renal cancer and metastatic disease", *Brit J Urol-Int*, **88(8)**, 818-824 (**2001**).

- 35.** Zigeuner R, Droschl N, Tauber V, Rehak P, Langner C, "Biologic significance of fascin expression in clear cell renal cell carcinoma: Systematic analysis of primary and metastatic tumor tissues using a tissue microarray technique", *UROLOGY* 68(3):518-22 (2006).
- 36.** Leibovich BC, Blute ML, "Surgical management of renal cell carcinoma", *SEMINARS IN ONCOLOGY* 68(3):518-522 (2006).
- 37.** Healy KA, Marshall FF, Ogan K, "Cytoreductive nephrectomy in metastatic renal cell carcinoma", *EXPERT REVIEW OF ANTICANCER THERAPY* 6(8):1295-304, (2006)

- 38.** Schrader AJ, Varga Z, Pfoertner S, Goelden U, Buer J, Hofmann R, "Treatment targeted at vascular endothelial growth factor: a promising approach to managing metastatic kidney cancer", *BJU INTERNATIONAL* 97(3):461-5 (2006).
- 39.** Schrader AJ, Varga Z, Hegele A, Pfoertner S, Olbert P, Hofmann R, "Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches", *JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY* 132(3):137-49 (2006).
- 40.** Petraki CD, Gregorakis AK, Vaslamatzis MM, Papanastasiou PA, Yousef GM, Levesque MA, Diamandis EP, "Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma", *TUMOR BIOLOGY* 27(1):1-7 (2006).
- 41.** Cindolo L, Patard JJ, Chiodini P, Schips L, Ficarra V, Tostain J, de La Taille A, Altieri V, Lobel B, Zigeuner RE, Artibani W, Guille F, Abbou CC, Salzano L, Gallo C, "Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy - A multicenter: European study", *CANCER* 104(7):1362-71 (2005).
- 42.** Sengupta S, Leibovich BC, Blute ML, Zincke H, "Surgery for metastatic renal cell cancer", *WORLD JOURNAL OF UROLOGY* 23(3):155-60 (2005).
- 43.** Zigeuner R, Ratschek M, Langner C, "Kit (CD117) immunoreactivity is rare in renal cell and upper urinary tract transitional cell carcinomas", *BJU INTERNATIONAL* 95(3):315-8 (2005).
- 44.** Galanis E, Burch PA, Richardson RL, Lewis B, Pitt HC, Frytak S, Spier C, Akporiaye ET, Peethambaram PP, Kaur JS, Okuno SH, Unni, KK, Rubin J, "Intratatumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma", *CANCER* 101(11):2557-66 (2004).
- 45.** Schrader AJ, von Knobloch R, Heidenreich A, Buer J, Hofmann R, "Application of retinoids in the treatment of renal cell carcinoma - a futile effort?", *ANTI-CANCER DRUGS* 15(9):819-24 (2004).
- 46.** Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M, Mueller GA, Mueller CA, Flad T, "Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients", *LABORATORY INVESTIGATION* 84(7):845-56 (2004).
- 47.** Kim HL, Belldegrun AS, Figlin RA, "Immune gene therapy for kidney cancer: The search for a magic trigger", *MOLECULAR THERAPY* 7(2):153-4 (2003).
- 48.** Tanaka Y, Sasaki M, Kaneuchi M, Fujimoto S, Dahiya R, "Single nucleotide polymorphisms of estrogen receptor alpha in human renal cell carcinoma", *BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS* 296(5):1200-6 (2002).
- 49.** Lee F, Patel HRH, "Kidney cancer: current management guidelines", *HOSPITAL MEDICINE* 63(4):214-7 (2002).

* Kırkalı, Z., **E. Tüzel**, A.E. Canda ve M.U. Mungan, "Testis sparing surgery for the treatment of a sequential bilateral testicular germ cell tumor", *Int J Urol*, **8(12)**, 710-712 (2001).

50. Blesa JMG, Canales JL, Perez P, et al. , "Young male patient with bilateral synchronous testicular germ cell tumour. Considerations for partial orchiectomy", *CLINICAL & TRANSLATIONAL ONCOLOGY* 10(12): 850-852 (2008).

51. Kumar KGS, Barriere H, Carbone CJ, et al. , "Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis", *JOURNAL OF CELL BIOLOGY* 179(5): 935-950 (2007).

52. Traub LM, Lukacs GL , "Decoding ubiquitin sorting signals for clathrin-dependent endocytosis by CLASPs", *JOURNAL OF CELL SCIENCE* 120(4) 543-553 (2007).

53. Thornton BR, Toczyski DP, " Precise destruction: an emerging picture of the APC", *GENES & DEVELOPMENT* 20 (22): 3069-3078 (2006).

54. Hughes PD, "Partial orchidectomy for malignancy with consideration of carcinoma in situ", *ANZ JOURNAL OF SURGERY* 76 (1-2): 92-94 (2006)

55. Yossepowitch O, Baniel J, "Role of organ-sparing surgery in germ cell tumors of the testis", *UROLOGY* 63 (3): 421-427 (2004).

56. Chandak P, Shah A, Taghizadeh A, et al, "Testis-sparing surgery for benign and malignant testicular tumours", *INTERNATIONAL JOURNAL OF CLINICAL PRACTICE* 57 (10): 912-913 (2003).

57. Theodore C, Terrier-Lacombe MJ, Laplanche A, et al, "Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy", *BRITISH JOURNAL OF CANCER* 90 (1): 55-59 (2004).

58. Passarella M, Usta MF, Bivalacqua TJ, et al, "Testicular-sparing surgery: a reasonable option in selected patients with testicular lesions", *BJU INTERNATIONAL* 91 (4): 337-340 (2003).

* Başakçı, A., Z. Kırkalı, **E. Tüzel**, K. Yörükoğlu, U. Mungan ve M. Sade, "Estrogen receptor expression in transitional cell carcinoma of the urinary bladder", *Eur Urol*, **41(3)**, 342-345 (2002).

59. Prizment AE, Anderson KE, Harlow BL, et al, "Reproductive risk factors for incident bladder cancer: Iowa Women's Health Study", *INTERNATIONAL JOURNAL OF CANCER* 120 (5): 1093-1098 (2007).

60. Shen SS, Smith CL, Hsieh JT, et al, "Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue", *CANCER* 106 (12): 2610-2616 (2006).

61. Croft PR, Lathrop SL, Feddersen RM, et al, "Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma", *ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE* 129 (2): 194-199 (2005)

62. Biglia N, Gadducci A, Ponzzone R, et al, "Hormone replacement therapy in cancer survivors", *MATURITAS* 48 (4): 333-346 (2004).

* Özer, E., K. Yörükoğlu, Ö. Sağol, M.U. Mungan, D. Demirel, **E. Tüzel** ve Z. Kırkalı, "Prognostic significance of nuclear morphometry in renal cell carcinoma", *Brit J Urol-Int*, **90(1)**, 20-26 (2002).

63. Novara G, Martignoni G, Artibani W, et al, "Grading systems in renal cell carcinoma", *JOURNAL OF UROLOGY* 177 (2): 430-436 (2007).

64. Uzunlar AK, Sahin H, Yilmaz F, et al, "Expression of p53 oncoprotein and bcl-2 in renal cell carcinoma", *SAUDI MEDICAL JOURNAL* 26 (1): 37-41 (2005).

65. Kırkalı Z, Lekili M, "Renal cell carcinoma: new prognostic factors?", *CURRENT OPINION IN UROLOGY* 13 (6): 433-438 (2003)

66. Oya M, Murai M, "Renal cell carcinoma: Relevance of pathology", *CURRENT OPINION IN UROLOGY* 13 (6): 445-449 (2003).

* Kırkalı, Z., H. van Poppel, **E. Tüzel**, M.U. Mungan, D. Jacqmin ve G. Mischkisch, "A prospective survey of surgical approaches in clinically localized renal cell carcinoma", *Uro-Oncology*, **2(4)**, 169-174 (2002).

67. Dillenburg W, Poulakis V, Skriapas K, de Vries R, Ferakis N, Witzsch U, Melekos M, Becht E, "Retroperitoneoscopic versus open surgical radical nephrectomy for large renal cell carcinoma in clinical stage cT2 or cT3a: Quality of life, pain and reconvalescence", *EUROPEAN UROLOGY* 49(2):314-22 (2006).

68. Van Poppel H, "Conservative vs radical surgery for renal cell carcinoma", *BJU INTERNATIONAL* 94(6):766-8 (2004).

* **Tüzel, E.**, M.U. Mungan, K. Yörükoğlu, A. Basakci ve Z. Kırkalı, "Primary renal lymphoma of mucosa associated lymphoid tissue", *Urology*, **61(2)**, 413 (2003).

69. Cohen SM, Petryk M, Varma M, Kozuch PS, Ames ED, Grossbard ML, "Non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue", *ONCOLOGIST* 11(10):1100-17 (2006).

70. Mortlock AM, Lim CSE, Morgan H, Wong TW, Joshi A, Kuttikat A, Chakravarty K, "Renal MALToma: an unusual lymphoma in a patient with lupus", *LUPUS* 15(9):613-5 (2006).

71. Qiu L, Unger PD, Dillon RW, Strauchen JA, "Low-grade mucosa-associated lymphoid tissue lymphoma involving the kidney - Report of 3 cases and review of the literature", *ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE* 130(1):86-9 (2006).

72. Zomas A, Leivada A, Gortzolidis G, Michalis E, Skandalis A, Anagnostopoulos NI, "Primary renal lymphoma presenting with chronic low-grade fever", *INTERNATIONAL JOURNAL OF HEMATOLOGY* 79(4):361-3 (2004).

* Kırkalı, Z., ve **E. Tüzel**, "Transitional cell carcinoma of the ureter and renal pelvis", *Crit Rev Hematol Oncol*, **47(2)**, 155-169 (2003).

73. Marin-Aguilera M, Menqual L, Ribal MJ, et al, "Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma", *EUROPEAN UROLOGY* 51 (2): 409-415 (2007).

- 74.** Bunnell JE, Tatu CA, Bushon RN, et al, "Possible linkages between lignite aquifers, pathogenic microbes, and renal pelvic cancer in northwestern Louisiana, USA", ENVIRONMENTAL GEOCHEMISTRY AND HEALTH 28 (6): 577-587 (2006).
- 75.** Brown GA, Busby JE, Wood CG, et al, "Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm?", BJU INTERNATIONAL 98 (6): 1176-1180 (2006).
- 76.** Zigeuner RE, Hutterer G, Chromecki T, et al, "Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location", BJU INTERNATIONAL 98 (6): 1181-1186 (2006).
- 77.** Kakizoe T, "Development and progression of urothelial carcinoma", CANCER SCIENCE 97 (9): 821-828 (2006).
- 78.** Langner C, Hutterer G, Chromecki T, et al, "Patterns of invasion and histological growth as prognostic indicators in urothelial carcinoma of the upper urinary tract", VIRCHOWS ARCHIV 448 (5): 604-611 (2006).
- 79.** Miyata Y, Kanda S, Ohba K, et al, "Tumor lymphangiogenesis in transitional cell carcinoma of the upper urinary tract: Association with clinicopathological features and prognosis", JOURNAL OF UROLOGY 176 (1): 348-353 (2006).
- 80.** Herawi M, Leppert JT, Thomas GV, et al, "Implants of noninvasive papillary urothelial carcinoma in peritoneum and ileocolonic neobladder: Support for "seed and soil" hypothesis of bladder recurrence", UROLOGY 67 (4): 746-750 (2006).
- 81.** Browne RFJ, Meehan CP, Colville J, et al, "Transitional cell carcinoma of the upper urinary tract: Spectrum of imaging findings", RADIOGRAPHICS 25 (6): 1609-1627 (2005).
- 82.** Renshaw AA, "Comparison of ureteral washing and biopsy specimens in the community setting", CANCER CYTOPATHOLOGY 108 (1): 45-48 (2006).
- 83.** Canales BK, Anderson JK, Premoli J, et al, "Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer", JOURNAL OF UROLOGY 175 (1): 74-77 (2006).
- 84.** Kim HJ, Lim JW, Lee DH, et al, "Transitional cell carcinoma involving the distal ureter-Assessment with transrectal and color Doppler ultrasonography", JOURNAL OF ULTRASOUND IN MEDICINE 24 (12): 1625-1633 (2005).
- 85.** Chew BH, Pautler SE, Denstedt JD, "Percutaneous management of upper-tract transitional cell carcinoma", JOURNAL OF ENDOUROLOGY 19 (6): 658-663 (2005).
- 86.** Lester PA, Rush HG, Sigler RE, "Renal transitional cell carcinoma and choristoma in a degu (Octodon degus)", CONTEMPORARY TOPICS IN LABORATORY ANIMAL SCIENCE 44 (3): 41-44 (2005).
- 87.** Bamias A, Deliveliotis C, Fountzilas G, et al, "Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: A study by the Hellenic Cooperative Oncology Group", JOURNAL OF CLINICAL ONCOLOGY 22 (11): 2150-2154 (2004).

* Tuna, B., K. Yörükoğlu, **E. Tüzel**, M. Güray, U. Mungan ve Z. Kırkalı, "Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer", *Pathol Res Pract*, **199(5)**, 323-328 (2003).

88. Lopez-Knowles E, Hernandez S, Kogevinas M, et al, "The p53 pathway and outcome among patients with T1G3 bladder tumors", *CLINICAL CANCER RESEARCH* 12 (20): 6029-6036 Part 1 (2006).

89. Yurakh AO, Ramos D, Calabuig-Farinas S, et al, "Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder", *EUROPEAN UROLOGY* 50 (3): 506-515 (2006).

90. Knowles MA, "Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?", *CARCINOGENESIS* 27 (3): 361-373 (2006).

91. Emerson RE, Cheng L, "Immunohistochemical markers in the evaluation of tumors of the urinary bladder - A review", *ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY* 27 (6): 301-316 (2005).

92. Dogan E, Saygili U, Tuna B, et al, "p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: A multivariate analysis", *GYNECOLOGIC ONCOLOGY* 97 (1): 46-52 (2005).

93. Rayburn E, Zhang RW, He J, et al, "MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy", *CURRENT CANCER DRUG TARGETS* 5 (1): 27-41 (2005).

* Birlik, M., S. Akar, **E. Tüzel**, F. Önen, E. Özer, M. Manisalı, Z. Kırkalı ve N. Akkoç, "Gemcitabine induced vasculitis in advanced transitional cell carcinoma of the bladder", *J Cancer Res Clin Oncol*, **130(2)**, 122-125 (2004).

94. Theodore C, Colombel M, "Prevention and management of the complications of concomitant radiochemotherapy (within the scope of conserving treatments of cancer infiltrating the bladder)", *PROGRES EN UROLOGIE* 16 (6): 796-798 Suppl. 2 (2006).

95. Bendix N, Glodny B, Bernathova M, et al, "Sonography and CT of vasculitis during gemcitabine therapy", *AMERICAN JOURNAL OF ROENTGENOLOGY* 184 (3): S14-S15 Suppl. (2005).

* Canda, A.E., **E. Tüzel**, M.U. Mungan ve Z. Kırkalı, "Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma", *Eur Urol*, **45(4)**, 465-470 (2004).

96. Redorta JP, Schatteman P, Perez JH, et al, "Intravesical instillations with bacillus Calmette-Guerin for the treatment of carcinoma in situ involving prostatic ducts", *EUROPEAN UROLOGY* 49 (5): 834-838 (2006).

97. Mungan MU, Canda AE, Tuzel E, et al, "Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder", *EUROPEAN UROLOGY* 48 (5): 760-763 (2005).

* Akçetin, Z., J. Todorov, **E. Tüzel**, D.G. Engehausen, F.S. Krause, R. Sauer, K.M. Schrott ve C. Rödel, "Radiochemotherapy after transurethral resection is an effective

treatment method in T1G3 bladder cancer", *Anticancer Res*, **25(3A)**, 1623-1628 (2005).

98. O'Donnell MA, Boehle A, "Treatment options for BCG failures", *WORLD JOURNAL OF UROLOGY* 24 (5): 481-487 (2006).

99. Weiss C, Wolze C, Engehausen DG, et al, "Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: An alternative to intravesical therapy or early cystectomy? ", *JOURNAL OF CLINICAL ONCOLOGY* 24 (15): 2318-2324 (2006).

* Mungan MU, Canda AE, Tüzel E, et al. , "Risk factors for mucosal prosthetic urethral involvement in superficial transitional cell carcinoma of the bladder", *Eur Urol* 48(5):760-763 (2005)

99. Oosterlinck W, Witjes F, Sylvester R , "Diagnostic and Prognostic Factors in Non-Muscle-Invasive Bladder Cancer and Their Influence on Treatment and Outcomes", *EUROPEAN UROLOGY SUPPLEMENTS*, 7(7): 516-523 (2008).

100. Babjuk M, Oosterlinck W, Sylvester R, et al. , "EAU Guidelines on Non-Muscle-Carcinoma of the Bladder", *ACTAS UROLOGICAS ESPANOLAS*, 33(4): 361-371 (2009).

101. Gofrit ON, Pode D, Pizov G, et al. , "Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-GuErin immunotherapy? ", *BJU INTERNATIONAL*, 103(7): 905-908 (2009).

102. Babjuk M, Oosterlinck W, Sylvester R, et al. , "EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder", *EUROPEAN UROLOGY*, 54(2): 303-314 (2008).

103. Ugurlu O, Gonulalan U, Adsan O, et al. , "Effects of simultaneous transurethral resection of prostate and solitary bladder tumors smaller than 3 cm on oncologic results", *UROLOGY*, 70(1): 55-59 (2007).

* Canda, A.E., M.U. Mungan, O. Yılmaz, K. Yörükoğlu, **E. Tüzel** ve Z. Kırkalı, "Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate", *Int Urol Nephrol*, **38(2)**, 275-280 (2006).

104. Hahn RG, Fagerstrom T, Tammela TLJ, et al. , "Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride", *BJU INTERNATIONAL* 99(3): 587-594 (2007).